Gilead presents new liver disease treatment data at EASL Congress

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a prominent player in the biotechnology industry with a market capitalization of $132.57 billion, is set to present new research findings at the upcoming European Association for the Study of the Liver (EASL) Congress, scheduled for May 7-10, 2025, in Amsterdam. The data highlight the company’s ongoing efforts in liver disease treatment, including primary biliary cholangitis (PBC) and hepatitis delta virus (HDV). According to InvestingPro analysis, Gilead maintains a strong financial position with a gross profit margin of 78.29% and robust revenue of $28.73 billion in the last twelve months.

The research includes a subgroup analysis from the ASSURE study and Phase 3 RESPONSE trial data, emphasizing the efficacy of Livdelzi (seladelpar) in reducing pruritus, a common symptom in PBC patients. The studies suggest that seladelpar may offer a sustained biochemical response for a broad range of PBC patients, regardless of prior treatment history. With an "GREAT" financial health score from InvestingPro, Gilead demonstrates strong capability to continue investing in breakthrough treatments. InvestingPro subscribers have access to 12 additional key insights about Gilead’s financial performance and market position.

Additionally, Gilead will present findings from two oral presentations on the maintained virologic response after treatment with bulevirtide in individuals with HDV. The MYR301 Phase 3 study will reveal long-term response rates, including the proportion of participants with undetectable virus levels two years post-treatment.

In the realm of hepatitis B (HBV), Gilead will share initial results from a Phase 1a study of a novel investigational therapeutic vaccine aimed at achieving a functional cure for HBV infection. Real-world data analyses will also be shared, including the risk of negative events in individuals with low-level HBV viremia and the impact of long-term tenofovir-based treatment on liver cancer risk.

For hepatitis C (HCV), the company will showcase real-world data demonstrating the effectiveness of direct-acting antivirals (DAAs) across different regions, supporting the global applicability of HCV treatment guidelines. Insights into reducing drug-drug interactions for HCV patients on DAAs and other medications will also be presented.

In support of EASL’s "Love Your Liver" campaign, Gilead will promote HCV screening awareness. The company is also launching "All the Feelings with PBC," a campaign in collaboration with the PBC Foundation, featuring the experiences of PBC patients through art.

The EASL Congress presentations underscore Gilead’s commitment to addressing unmet needs in liver disease treatment and the company’s pursuit of advancing scientific research in this field. This information is based on a press release statement from Gilead Sciences, Inc. For investors seeking comprehensive analysis of Gilead’s market position and financial outlook, InvestingPro offers detailed research reports and real-time metrics, including Fair Value calculations that currently suggest the stock is trading near its Fair Value.

In other recent news, Gilead Sciences Inc. reported its first-quarter 2025 earnings, which exceeded Wall Street expectations with an earnings per share (EPS) of $1.81 compared to the forecast of $1.77. However, the company’s revenue fell short, reaching $6.67 billion against the anticipated $6.78 billion. Despite the revenue miss, Gilead’s base business demonstrated resilience with a 4% year-over-year growth, driven by strong performance in the HIV treatment market, particularly with Biktarvy sales increasing by 7% to $3.1 billion. The company is also preparing for multiple product launches, including lenacapavir for PrEP and Trodelvy for metastatic triple-negative breast cancer.

Additionally, Gilead provided a full-year total product sales guidance of $28.2 billion to $28.6 billion, with flat HIV sales expected in 2025 due to the Medicare Part D redesign. In other developments, S&P upgraded Gilead’s long-term debt rating from BBB+ to A-, citing a positive outlook for the company’s HIV franchise and other products. The company remains optimistic about its upcoming product launches and continues to focus on effective cost management, as evidenced by decreased R&D and SG&A expenses. Despite competitive pressures in the cell therapy market, Gilead is confident in its strategic position and diverse pipeline, anticipating several potential product launches in the near future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.